Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Doximity was filed in the last 90 days. The latest on record was on May 27, 2022.
How often do Doximity insiders buy and sell shares?
Since 2021, Doximity insiders reported 4 open-market purchases and 143 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2022.
Who is selling Doximity stock?
In the last 90 days, 4 insiders of Doximity (DOCS) reported 9 open-market sales worth $854K in total on SEC Form 4. The largest seller by value was Timothy S Cabral, with $375K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade DOCS?
Yes. Members of Congress disclosed 1 trade in Doximity (DOCS) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Rep. Jonathan L. Jackson (IL01).
When does Doximity report its next results?
Doximity's next results are expected on Feb 3, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−38.1% (−$17.69) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $46.42 on Nov 20, 2025 to $28.73 on Nov 20, 2026 (−38.1%). Disclosed in this range: 0 insider trades, 23 pre-arranged insider sales, 0 Congress trades, and 15 13F position changes for 4 quarters ending in it.
$10$20$40$50$60$28.73
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 23 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Technology company based in San Francisco, California.
Last 12 months
−38.1%
S&P 500 +5.7% over the same dates
Market value
$5.12B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 6.95M shares sold short (3.9% of shares outstanding), −23.5% vs the previous count, 2.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$175M
+3.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$93.3M
This quarter $93.3M, a year earlier $93.9M
Net debt
—
Debt —, cash $219M, at Sep 30, 2026
Net income, last 12 months
$140M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Insiders of Doximity reported 4 open-market purchases and 143 sales since 2021; purchases in 2 different years, most recently 2022.
Year
Bought
Sold
2026
—
$1.96M21×21 trades
2025
—
$104M55×55 trades
2024
—
$11.8M29×29 trades
2023
—
$3.21M14×14 trades
2022
$585K2×2 trades
$2.74M13×13 trades
2021
$40.3M2×2 trades
$237M11×11 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Owners above 5%
No Schedule 13D or 13G filing on DOCS over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Red flags in its filings
Apr 17
Top officer leaving
“On April 13, 2026, the Company accepted her resignation as Chief Financial Officer.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Since Nov 19, 2025, DOCS is down 40.1% and the index fund is up 4.1%: 44 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much DOCS moves
A usual day
±1.7%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
5.1%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−23.0%May 14, 2026
Largest one-day rise
+32.6%Aug 7, 2026
Deepest fall of the year
−65.0%From the close of Dec 3, 2025 to May 14, 2026.
Days of 5% or more
27Out of 252 sessions, in either direction.
Beta 0.7(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Doximity filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 23 open-market sales (about $2.56M, in 23 filings, by 4 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 54 open-market sales (about $103M, in 27 filings). (Doximity on OQRO)
Congress. Members of Congress filed 1 disclosure on Doximity in the 12 months to Nov 19, 2026: 0 purchases and 1 sale, by 1 member. In the 12 months before that: 1 disclosure. The largest range: Rep. Jonathan L. Jackson (IL01), $15,001 to $50,000, filed Dec 5, 2025.
Funds and stakes. Fund 13F filings recorded in the 12 months show 7 new or larger positions and 8 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for DOCS on the settlement date of Oct 30, 2026 was 6,945,987 shares (-23.54% on the previous report), about 2.68 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 117,814 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Doximity filed a Form 8-K on May 13, 2026 (Items 2.02, 5.02) that OQRO classes as: changed a top executive or board member, and reported its results. The company's own opening sentence of that report reads: "On May 13, 2026, Doximity, Inc. (the 'Company') announced the appointment of Matthew Sonefeldt as Chief Financial Officer of the Company, effective May 13, 2026."
Who holds it. 356 funds reported a stake in Doximity in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (11.2% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (4.7% of the value reported).
Attention. The English Wikipedia article on Doximity was read about 46 times a day in the 7 days to Nov 18, 2026, against a usual 42 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Doximity filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 23 open-market sales (about $2.56M, in 23 filings, by 4 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 54 open-market sales (about $103M, in 27 filings).
The largest sale: Timothy S Cabral, Director, about $500K, filed Nov 25, 2025.
Congress
Members of Congress filed 1 disclosure on Doximity in the 12 months to Nov 19, 2026: 0 purchases and 1 sale, by 1 member. In the 12 months before that: 1 disclosure.
The largest range: Rep. Jonathan L. Jackson (IL01), $15,001 to $50,000, filed Dec 5, 2025.
Funds and stakes
Fund 13F filings recorded in the 12 months show 7 new or larger positions and 8 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for DOCS on the settlement date of Oct 30, 2026 was 6,945,987 shares (-23.54% on the previous report), about 2.68 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 117,814 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $19.6M for its principal executive officer, and an average of $2.17M for the other named executive officers.
Company reports, price and press
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Doximity filed 0 open-market purchases and 3 open-market sales (about $525K, in 3 filings, by 3 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 3 open-market sales (about $172K, in 3 filings). (Doximity on OQRO)
Funds and stakes. Fund 13F filings recorded in the 30 days show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for DOCS on the settlement date of Oct 30, 2026 was 6,945,987 shares (-23.54% on the previous report), about 2.68 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 117,814 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Doximity filed a Form 8-K on Nov 5, 2026 (Item 2.02) that OQRO classes as: reported its results. Press coverage listed by Finnhub: "DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems" (Yahoo, Nov 16, 2026).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Doximity filed 0 open-market purchases and 3 open-market sales (about $525K, in 3 filings, by 3 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 3 open-market sales (about $172K, in 3 filings).
The largest sale: Timothy S Cabral, Director, about $375K, filed Nov 9, 2026.
Funds and stakes
Fund 13F filings recorded in the 30 days show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for DOCS on the settlement date of Oct 30, 2026 was 6,945,987 shares (-23.54% on the previous report), about 2.68 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 117,814 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2026, the company's proxy statement reported total compensation of $19.6M for its principal executive officer, and an average of $2.17M for the other named executive officers.
Company reports, price and press
Doximity filed a Form 8-K on Nov 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
Press coverage listed by Finnhub: "DOCS Expands Clinical AI Tools Across Three Major U.S. Health Systems" (Yahoo, Nov 16, 2026).
Press coverage listed by Finnhub: "Doximity to Provide New Clinical AI Tools Across NewYork-Presbyterian, Columbia University and Weill Cornell Medicine" (Yahoo, Nov 13, 2026).
Press coverage listed by Finnhub: "Doximity CEO Jeff Tangney on Putting Doctors First as AI Rewrites Healthcare" (Yahoo, Nov 11, 2026).
Doximity filed a Form 8-K on May 13, 2026 (Items 2.02, 5.02) that OQRO classes as: changed a top executive or board member, and reported its results.
The company's own opening sentence of that report reads: "On May 13, 2026, Doximity, Inc. (the 'Company') announced the appointment of Matthew Sonefeldt as Chief Financial Officer of the Company, effective May 13, 2026."
Doximity filed a Form 8-K on Apr 17, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On April 13, 2026, the Company accepted her resignation as Chief Financial Officer. Effective February 3, 2026, the Company’s Board of Directors appointed Siddharth Sitaram, the Company’s Chief Accounting Officer, to serve as the..."
Doximity filed a Form 8-K on Feb 5, 2026 (Items 2.02, 5.02) that OQRO classes as: changed a top executive or board member, and reported its results.
The company's own opening sentence of that report reads: "On February 5, 2026, Doximity, Inc. ('Doximity' or the 'Company') announced that Anna Bryson, the Company’s Chief Financial Officer, principal financial officer, and principal accounting officer, is taking a temporary medical lea..."
DOCS closed at $30.67 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $31.45 to $30.67, a change of −2.5%.
Who holds it
356 funds reported a stake in Doximity in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (11.2% of the value reported), VANGUARD PORTFOLIO MANAGEMENT LLC (5.0% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (4.7% of the value reported).
Attention
The English Wikipedia article on Doximity was read about 46 times a day in the 7 days to Nov 18, 2026, against a usual 42 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
DOCS closed at $28.73 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $33.58 to $28.73, a change of −14.4%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
People read Doximity's Wikipedia article about 45 times a day over the last week, close to the 43 on a usual day of the three months before.
May 16, 2026Busiest day: 370 views on Aug 7, 2026Nov 21, 2026
Views of the article Doximity, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
When insiders usually buy
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 3, 2027
Purchases after results
Not enough history
From Doximity's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Doximity's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Off-exchange trading: 39.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (25.7% on ATS, 13.3% with other brokers), close to its 26-week average of 37.4%. Weeks of Oct 5 to Oct 30, 2026.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
By product or service
Subscription$163M93%
+2.0% on the same quarter a year earlier ($159M)
Other$11.9M6.8%
+32% on the same quarter a year earlier ($9.06M)
Total revenue$175M+3.6%
The full fiscal year ended Mar 31, 2026
Fiscal year Apr 1, 2025 to Mar 31, 2026, from the annual report filed May 19, 2026. Read the filing
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: INTELLIGENT CROSS LLC (13.0%), UBS ATS (11.4%), MS TRAJECTORY CROSS (ATS-1) (10.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
By product or service
Subscription$608M94%
+12% on the year before ($544M)
Other$36.5M5.7%
+37% on the year before ($26.6M)
Total revenue$645M+13%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We are the leading digital platform for U.S. medical professionals, with over 3 million registered members2 as of March 31, 2026. Our registered members represent more than 85% of U.S. physicians, spanning all 50 states and every medical specialty, along with two-thirds of U.S. nurse practitioners and physician assistants, and approximately 90% of graduating U.S. medical students. As of March 31, 2026, the total number of U.S. physicians was approximately 1 million. We calculate U.S. physicians as all U.S. physicians (MDs/DOs) who are under the age of 76, not retired, hold an active medical license, and have a physician status on the National Provider Identifier (NPI) registry. To be included in our calculation of registered members as a percentage of U.S.
What the section covers (30 headings)
Overview
Impact of Macroeconomic Events
Key Business and Financial Metrics
Components of Results of Operations
Revenue
Cost of Revenue
Gross Profit and Gross Margin
Operating Expenses
Research and Development
Sales and Marketing
General and Administrative
Restructuring and Impairment Charges
Other Income, Net
Provision for Income Taxes
And 16 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed May 19, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed May 19, 2026, compared with the one filed May 20, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Our development, deployment, and use of artificial intelligence may not achieve the expected benefits and may create operational, reputational, competitive, regulatory, legal, and liability risks.
Legal proceedings (Item 3)
Beginning in April 2024, the Company and certain of our directors and officers have been named in lawsuits in the United States District Court for the Northern District of California. The first lawsuit (the “securities lawsuit”) is captioned In re Doximity, Inc. Securities Litigation, No. 5:24-cv-02281 (N.D. Cal.). The operative complaint brings securities law claims on behalf of a putative class of our investors from June 24, 2021 and August 8, 2023 against the Company and our CEO related to our disclosure of user count and engagement rates.
Source: SEC EDGAR, Form 10-K filed May 19, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.